The INVEST Precision Medicine conference cast a spotlight on the role of children's hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
Experts in precision medicine provide a broad overview of where we are and where we need to go to make the promise and potential of this sector a reality.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
On the final day of INVEST Precision Medicine, a panel with Caris Health, CVS Health, and Intermountain Healthcare will share assessments of precision medicine's progress and the outlook for this sector. Also, a panel will highlight non dilutive funding opportunities for startups. Register now!
Can an industry coalition help craft policy to support the use of Real-World Evidence? Five prominent real-world data and analytics companies are betting on it, launching the RWE Alliance.
The organizations will collaborate on efforts to pull real-world data from a number of sources including EHRs, data registries and testing labs and determine their utility in making regulatory decisions.
The New York-based drugmaker marks the third major biopharma company to partner with the San Francisco-based firm, after Amgen and Roche.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Biden Cancer Initiative has announced that multiple healthcare organizations — including BreastCancerTrials.org, IBM Watson Health, Massive Bio and Syapse — are creating a shared platform called the Oncology Clinical Trial Information Commons, which will help cancer patients to know their clinical trial options.
Integrating the NCCN's Biomarker Compendium data into Syapse's products is designed to aid finding targeted drugs and clinical trials while improving physician workflow.
It’s time for entrepreneurs and purchasers to remember that the patient isn’t a component of a healthcare technology plan, they are the point of it.
“Life science companies recognize that they need to be able to work more closely with providers,” said Syapse CEO Ken Tarkoff.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
At MedCity’s CONVERGE conference July 31-August 1 in Philadelphia next week, I’m speaking on some of the challenges that are holding back precision medicine.
What will it take for precision medicine to be widely utilized in the oncology space? Jonathan Hirsch, founder and president of Syapse, shared his insights.
In a CNBC interview, Chamath Palihapitiya, CEO and founder of Social Capital, shot down IBM and its Watson platform.
The University of Miami Health System's Sylvester Comprehensive Cancer Center and Syapse have formed a new precision medicine initiative.
The network enables comprising 79 hospitals in 11 states to share anonymous cancer patient genomic data.